Table 1.
Baseline characteristics—full analysis set.
| Degarelix (N=142) | Goserelin (N=141) | |
|---|---|---|
| Median age (range), year | 75 (52–86) | 73 (47–91) |
| Median baseline BMI (range), kg/m2 | 23.3 (16.9–34.9) | 22.7 (14.5–32.6) |
| Median testosterone (range), ng/mL | 4.6 (1.3–9.6) | 4.6 (1.7–11.2) |
| Median PSA (range), ng/mL | 89.4 (2.4–8 000) | 131 (2.6–8 000) |
| 5-alpha reductase therapy, n (%) | 23 (16) | 17 (12) |
| Disease stage, n (%) | ||
| Localised | 35 (25) | 33 (23) |
| Locally advanced | 13 (9) | 17 (12) |
| Metastatic | 89 (63) | 85 (60) |
| Not classifiablea | 5 (4) | 6 (4) |
| Gleason score (at diagnosis), n (%) | ||
| 2–4 | 1 (<1) | 1 (<1) |
| 5–6 | 17 (12) | 16 (11) |
| 7–10 | 124 (87) | 124 (88) |
| Median time since diagnosis (range), day | 14 (4–3 012) | 14 (6–1 133) |
BMI, body mass index; PSA, prostate-specific antigen.
a
Not classifiable was chosen when an investigator could not medically conclude that a patient's prostate cancer was definitely localised, locally advanced or metastatic.